Sellas reports Q2 2026 results, nears key REGAL trial milestone

Sellas Life Sciences Group reported second quarter 2026 financial results and a corporate update on August 11, 2026. The company said it is nearing the pre-specified 80th event in the Phase 3 REGAL trial, a step the company described as critical toward the final efficacy analysis and, if successful, a possible Biologics License Application submission to the FDA¹. Sellas said that once the required pre-specified 80th event occurs, it will trigger a database lock, blinded data review, unblinding, and disclosure of topline results¹.

In its Phase 2 trial of SLS009 in newly diagnosed AML, the company reported that 28 patients have been enrolled, with enrollment and dosing continuing in the 80-patient study, which includes patients who become refractory early to AZA/VEN treatment identified through transcriptomic, genomic, and proteomic profiling¹. Topline data from that trial are expected in the fourth quarter of 2026.¹

Sellas also disclosed preclinical findings on SLS009 in pancreatic cancer, saying the drug has shown activity as a single agent in pancreatic ductal adenocarcinoma cells that are largely resistant to leading RAS inhibitors, and can act together with RAS-inhibiting drugs¹. The company said data from these preclinical experiments are expected to be presented at an upcoming medical conference.¹

On finances, Sellas reported cash and cash equivalents of approximately $138.3 million as of June 30, 2026¹. Net loss was $9.6 million for the second quarter of 2026, or $0.05 per basic and diluted share, compared with a $6.6 million loss a year earlier; for the first half of 2026, net loss was $18.0 million, or $0.10 per share, versus $12.4 million in the same period of 2025.¹